Have your say
On the availability of mirvetuximab soravtansine (Elahere) as a treatment for patients with platinum resistance.
The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending that mirvetuximab soravtansine (Elahere) should not be used by the NHS in England for patients with platinum-resistant ovarian cancer. It is important to note that this is draft guidance and is not NICE's final decision.
Ovacome has met with NICE to understand where your views and experiences can be most impactful, and we have created a short survey to capture the evidence they seek.
We understand that there are a number of surveys about the NICE draft guidance for mirvetuximab soravtansine. Ovacome has been working with NICE so that we know where there are gaps in understanding. You may have already responded to a survey on this issue, but please also give your views in our survey below. The information you give us will be collated and sent to NICE when this survey closes at 12pm on 16 January 2026. Please note, we have been granted an extension to ensure that as many of our community as possible are able to have their views heard.
Your views and opinions are important. Please complete our survey by 12pm on 16 January 2026 to have your say.
If you need help in completing this survey, further information, or support, our team are here to help.
You can call the Ovacome support line on 0800 008 7054.
We're open Monday to Friday, 10am - 5pm.
Further information
The initial NICE committee meeting was to consider whether mirvetuximab soravtansine (also called Elahere) should be made available to treat folate receptor- alpha (FR-alpha)-positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults after 1 to 3 lines of systemic treatment.
Usual treatment for this type of advanced ovarian cancer is chemotherapy. You can find out more about this in our booklet: Treatment for relapsed ovarian cancer. While clinical trial evidence shows mirvetuximab soravtansine increases how long people have before their condition gets worse and how long they live compared with chemotherapy, there was a lack of evidence in some areas.
NICE has initially concluded that the treatment is not cost effective.
Ovacome has met with NICE to understand where your views and experiences can be most impactful. NICE are keen to hear from patients about:
- The severity of chemotherapy treatment, so that they can take this in to account in their decision making
- The difference in quality of life for people having mirvetuximab soravtansine and people having chemotherapy
There will be a second committee meeting in Spring 2026. Ovacome will be at that meeting, prior to that meeting we want to present the data from the survey to NICE. Your views and opinions are important.
Ovacome has applied to NICE for, and been granted, an extension to submit the survey data and your views. The public survey undertaken by NICE will close on the 17 December and the Ovacome survey will close at 12pm on the 16 January 2026.
If you are already taking the treatment you can continue to do so until you and your clinical team decide it is appropriate to stop.
Platinum resistance is when cancer has come back less than six months after finishing platinum-based chemotherapy, such as carboplatin or cisplatin.
This is called platinum resistant cancer. Your oncologist will explain whether they think you will benefit from further treatment with platinum chemotherapy, or not. If the cancer never improved with platinum-based chemotherapy this is called platinum refractory ovarian cancer.
If your tumour responded well to platinum chemotherapy, but still came back within six months, your oncologist may recommend trying a different platinum combination from your first line treatment.
In these situations, your oncologist will discuss treatment options with you such as paclitaxel (Taxol) or liposomal doxorubicin (Caelyx).
Some centres offer weekly chemotherapy treatments for platinum resistant ovarian cancer.
If approved, mirvetuximab soravtansine (Elahere) would be considered as a type of targeted therapy. Clinical trials have found that people who received mirvetuximab soravtansine (Elahere) had an improvement in progression free and overall survival, but NICE has initially concluded that the treatment is not cost effective.
Become part of the Ovacome community
Our members are at the heart of everything we do. There’s no cost to membership. Be the first to hear about Ovacome news and join a friendly, supportive community, all working together to promote knowledge and support others.
